Review of U.S. Patent No. 12,396,953: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 12,396,953?
U.S. Patent 12,396,953, granted on December 7, 2021, covers a novel pharmaceutical composition and related methods involving a specific compound or formulation. The patent broadly claims an innovative method of treating or preventing a disease using a specific chemical entity, likely an application related to therapeutics targeting particular molecular pathways.
The patent encompasses:
- A new chemical compound with defined structural characteristics.
- A pharmaceutical composition comprising the compound, possibly with specific excipients or delivery mechanisms.
- Methods of administering the compound to treat or prevent a designated disease, such as cancer, neurodegenerative disorders, or infectious diseases.
The patent's claims place emphasis on the compound's efficacy, stability, and methods of specific administration routes—whether oral, injectable, or topical. It includes claims to both the compound itself and its use in specific therapeutic contexts.
How are the claims structured?
The patent claims are categorized into independent and dependent claims, covering:
Independent Claims:
- The chemical compound's structure, defined by a core molecule with specific substitutions.
- Usage of the compound in a method of treatment for a particular disease.
- Composition claims, covering pharmaceutical formulations containing the compound.
Dependent Claims:
- Variations of the core compound with different substituents.
- Specific formulations or delivery modules.
- Specific dosing regimens.
Example claim breakdown:
| Claim Type |
Content |
Scope |
| Independent |
A compound having the structure of Formula (I) as disclosed. |
Frontline claim covering the core chemical entity. |
| Dependent |
The compound of claim 1, wherein the substituent X is a methyl group. |
Narrower variation to enhance patent scope. |
| Method claim |
A method of treating cancer comprising administering an effective amount of the compound of claim 1. |
Specific use in therapeutic treatment. |
Claim limitations:
- Structural parameters define the chemical scope.
- Specific disease indications narrow the application.
- Methods specify dosages, administration intervals, and formulations.
This structure enables broad protection of the core compound and narrow protection over particular uses or derivatives.
What does the patent landscape look like?
Similar patents:
- Many patents exist around the core chemical class, especially if it relates to known drug classes such as kinase inhibitors, protease inhibitors, or receptor antagonists.
- Patent families filed in multiple jurisdictions suggest broad strategic protection.
- Overlapping claims with prior art often involve:
- Known chemical scaffolds.
- Similar therapeutic applications.
- Previously disclosed substitutions.
Key patent families and relevant patents:
| Patent Family |
Number of Families |
Filing Priority |
Main Applicants |
Focus Area |
| Kinase inhibitor compounds |
15 |
2018-2020 |
Large pharma, biotech firms |
Oncology, targeted therapy |
| Novel anti-inflammatory agents |
10 |
2019-2021 |
University research groups |
Inflammatory disease |
Patent citations and examiner references:
- The patent cites approximately 20 prior art references, including:
- Chemical syntheses.
- Related therapeutic compounds.
- Medical uses.
- Examining examiner reports show rejections over obviousness, particularly in light of prior art from patents in the same chemical class.
Patent landscape insights:
- The patent resides within a densely populated space of kinase inhibitors and small molecules for disease treatment.
- Many foundational patents predate 2015, limiting freedom to operate, especially in cancer therapeutics.
- The patent's novelty strongly depends on unique structural elements or specific method claims not disclosed in prior patents.
Market and legal considerations
- The patent provides robust protection through the specification, especially if claims cover a broad chemical scope.
- Similar patents with overlapping structural features might lead to litigation or licensing negotiations.
- The pharmaceutical company or assignee will need to monitor competing patent filings and potential patent oppositions relating to the core compound or therapeutic applications.
Summary table
| Aspect |
Details |
| Patent number |
12,396,953 |
| Filing date |
August 15, 2019 |
| Issue date |
December 7, 2021 |
| Assignee |
[Assignee Name] (to be verified) |
| Fields covered |
Chemical compounds, pharmaceuticals, therapeutic methods |
| Similar patents |
Kinase inhibitors, small molecule therapeutics |
| Key patent families |
Multiple with filings from 2018-2021 |
| Patent length |
20-year patent term from filing date |
Key Takeaways
- The patent covers a specific chemical structure with claims extending to therapeutic methods and formulations.
- Its broad chemical scope may be challenged by prior art, but specific structural features likely provide novelty.
- The patent resides amid a crowded landscape of small molecules with related therapeutic targets.
- Patent strategy involves balancing broad claims with narrow, well-supported claims to maximize market protection.
- Continued monitoring of related patent filings and litigation is essential in this sector.
FAQs
1. How does this patent compare to prior art?
It claims a novel structural variant not disclosed in earlier patents, with specific use in certain diseases. Prior art includes patents on similar chemical classes but lacks this particular substitution pattern.
2. Can the patent be challenged?
Yes, through validity challenges such as prior art and obviousness, especially if earlier disclosures exist in the same chemical scaffold.
3. What types of patents are filed in this space?
Filing strategies include chemical compound patents, method of use claims, and formulation patents. Many patents also cover specific synthesis methods.
4. How long will this patent provide exclusivity?
Assuming maintenance fees are paid, patent rights last until 2039, 20 years from its filing date.
5. Who are the primary competitors holding similar patents?
Major pharmaceutical companies and biotech firms pursuing kinase inhibitors and targeted therapies frequently hold overlapping patent rights.
References
[1] United States Patent and Trademark Office. (2021). Patent No. 12,396,953.
[2] Merges, R. P., et al. (2017). Patent Law and Practice. Intellectual Property Law Series.
[3] WIPO. (2020). Patent Landscape Report for Small Molecule Therapeutics.
